While CCR2 blockade has failed in RA clinical trials, previous studies support CCR7 as a therapeutic target in RA, thus the increased expression of CCR7 in ACPA+ compared to ACPA− RA synovial tissue might result in increased sensitivity of ACPA+ RA to CCR7 inhibition [39,40]. This evidence concerns the gene CCR7 and rheumatoid arthritis.